Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

PARIS and LAUSANNE, Switzerland, September 7 /PRNewswire/ -- Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.

CDC25 is a key enzyme involved in the regulation of cell cycle. Its over-expression is associated with the progression of cancer. By blocking the cell cycle and thus interrupting tumour growth, Debio 0931 represents a promising novel target for cancer therapies. This preclinical candidate will now be the subject of a full development program under the responsibility of Debiopharm.

Under the terms of the agreement Debiopharm will be exclusively responsible for the development of Debio 0931, with Ipsen having an option to re-acquire development and commercialisation rights post completion of Phase II clinical trials. Ipsen will receive an upfront payment and be eligible for milestone payments and royalties.

Jean-Luc Belingard, Ipsen's Chairman and Chief Executive Officer said: "We are delighted that Ipsen's CDC25 inhibitor will be progressed toward clinical development by Debiopharm, a company with a strong track record in oncology. Debiopharm is our long-standing partner with whom we have had a very fruitful partnership in other areas of oncology for more than 20 years and we feel confident that the full potential of CDC25 will be maximised, thanks to Debiopharm's strong expertise in oncology development."

Rolland-Yves Mauvernay, President and Founder of Debiopharm Group added: "We are extremely pleas
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) ... Market by Products, by Testing services - Global Forecast ... The global animal genetics market is estimated to be ... a CAGR of 8-9% during the forecast period of ... driven by increasing animal protein consumption, increasing adoption of ...
(Date:5/28/2015)... 28, 2015 Natera, Inc., a leader ... published in Ultrasound in Obstetrics & Gynecology ... non-invasive prenatal test (NIPT) can identify a complete ... A study based upon data collected in ... in about 1 in 1,000 pregnancies, although other ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... JOSEPH, Mich., Feb. 5 GeneGo, Inc., the ... has extended their,licensing agreement with GeneGo and have ... Bioinformatics, R&D and clinical studies,with global access to ... for functional analysis of biological OMICs data,featuring a ...
... Forest Laboratories, Inc.,(NYSE: FRX ) ... III study of,memantine HCl (currently marketed as ... novel once-daily formulation. The study evaluated,the efficacy, ... 28 mg,memantine extended-release, once-daily formulation compared to ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company ... targeting the chronic inflammation,underlying cardiovascular and neurological disease, ... present a Company Overview at BIO,CEO & Investor ... at 11:00,a.m. (ET) on Tuesday, February 12, 2008. ...
Cached Biology Technology:GSK Extends GeneGo License and Adds New Products 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 3Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 4Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Immunogenetics experts at The Children,s Hospital of Philadelphia ... characterize the genes that encode HLA molecules. The ... technology to type human leukocyte antigens (HLAs)--complex, highly ... to immune function. The new test may ...
... will be the subject of a symposium on Saturday, February 15, ... Advancement of Science in Chicago. The session, which features two ... Martin Chalfie, will take place 10:00-11:30 a.m. CST in Grand Ballroom ... the first 2014 winner of the Golden Goose Award ...
... aware of the health benefits of dietary fiber. But what ... Research at the University of Michigan Medical School, the University ... Sweden, has begun to uncover how our gut bacteria metabolize ... Trillions of bacteria live in human intestines - there are ...
Cached Biology News:CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3U-M scientists & colleagues investigate the fiber of our being 2
... Fiberboard boxes are ideal for use in refrigerators, freezers, ... racks. Four vibrant colors allow for color coding to ... liquid nitrogen drainage or promote cool air circulation. Supplied ... holds 100 tubes. Box dimensions: 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
REGULATED IN DEVELOPMENT AND DNA DAMAGE RESPONSES 1,HIF-1 responsive RTP801...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
Biology Products: